Loading…
BGM Group Ltd.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in BGM.
▼ -98.7% over 5Y.
today you would have $12.24▼ -98.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $3.69 | $8.45 | $3.86 | $3.69 | |
| P/E | — | — | — | — | 24.6x |
| P/S | 1.5x | 19.5x | 2.4x | 0.6x | 0.4x |
| P/B | 1.0x | 1.9x | 1.4x | 0.6x | 0.5x |
| EPS | -$0.18 | -$0.20 |
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| LENZLENZ Therapeutics, Inc. | $4.13 | — | 0.6x | — | -59.21% | $129.77M |
| APYXApyx Medical Corp | $3.08 | — | 12.2x | — | -90.69% | $129.74M |
| HCATHealth Catalyst, Inc. | $1.72 | — | 1.3x | — | -118.12% | $129.44M |
| INOInovio Pharmaceuticals Inc | $1.29 |
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. BGM Group Ltd. is based in Chengdu, China.
Company description provided by Yahoo Finance.
| -$1.08 |
| $0.15 |
| Dividend yield | — | — | — | 6.49% | — |
| Profit margin | -11.25% | -52.59% | -5.75% | -16.74% | 1.66% |
| ROE | -4.24% | -5.10% | -3.38% | -18.18% | 2.03% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Dividend growing 0.0% a year against a 9.0% required return, taken from the stock’s beta. The only method anchored on what the company pays rather than what it reports.
Not the average of the seven numbers above. Four of the seven start from the same earnings per share — Graham, Lynch, sector multiples and its own history — so averaging all seven would let one input count four times and drown out the others. Instead each family produces one number, and the fair price is the average of the families that answered. A family with two working formulas contributes their average, not two votes.
1 methods answered, across 1 families.
Every formula reads the same reported statements and they can be wrong together. The margin is room for that.
+748.2% from the average.
These are models, not forecasts, and not investment advice. Change one assumption and the number changes with it — that is a property of valuation, not a defect of this page.
| — |
| 24.3x |
| — |
| -409.87% |
| $133.38M |
| TLSATiziana Life Sciences Ltd | $1.01 | — | — | — | -924.32% | $128.53M |
| VANIVivani Medical, Inc. | $1.42 | — | 6.7x | — | -220.41% | $128.09M |